Celgene: agreement for acquisition of Juno Therapeutics
(CercleFinance.com) - Celgene has announced signing an agreement to merge with Juno Therapeutics, in which Celgene will offer 87 dollars in cash for each Juno share that it does not yet own, meaning a total of 9 billion dollars.
The American biotechnology company explains that this acquisition will bring JCAR017, which should be a significant growth driver beyond 2020, with global sales having the potential to peak at about 3 billion dollars.
At this time, Celgene confirmed its financial targets through to 2020, with total net product sales of between 19 billion and 20 billion dollars, and adjusted EPS of over 12.5 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The American biotechnology company explains that this acquisition will bring JCAR017, which should be a significant growth driver beyond 2020, with global sales having the potential to peak at about 3 billion dollars.
At this time, Celgene confirmed its financial targets through to 2020, with total net product sales of between 19 billion and 20 billion dollars, and adjusted EPS of over 12.5 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.